| General Information of Drug Metabolite (DM) (ID: DM006392) |
| DM Name |
Encorafenib dealkylation
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2D6 (CYP2D6)
|
DME0009
|
| Oxidation - N-dealkylation |
Encorafenib
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - N-dealkylation |
Encorafenib
|
[1] |
|
Mephenytoin 4-hydroxylase (CYP2C19)
|
DME0021
|
| Oxidation - N-dealkylation |
Encorafenib
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Encorafenib |
DR0578
|
Approved |
Melanoma |
|
|
| References |
| 1 |
Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
